Literature DB >> 30822416

Plasma free metanephrines for diagnosis of neuroblastoma patients.

Sebastiano Barco1, Iedan Verly2, Maria Valeria Corrias3, Stefania Sorrentino4, Massimo Conte4, Gino Tripodi1, Godelieve Tytgat5, André van Kuilenburg6, Maria van der Ham7, Monique de Sain-van der Velden7, Alberto Garaventa4, Giuliana Cangemi8.   

Abstract

INTRODUCTION: A substantial number of patients with neuroblastoma (NB) have increased excretion of catecholamines and metanephrines. Here, we have investigated the diagnostic role of plasma free metanephrines (PFM), metanephrine (MN), normetanephrine (NMN) and 3-methoxytyramine (3MT) for NB, the most common extra-cranial solid tumour in children.
METHODS: PFM were quantified by using a commercial IVD-CE LC-MS/MS method on a TSQ Quantiva coupled to an Ultimate 3000. The method was further validated on 103 samples from pediatric subjects (54 patients with histologically confirmed NB and 49 age and sex matched controls). Correlations between PFM concentrations with clinical factors were tested. We directly compared MN, NMN, and 3MT concentrations in matched plasma and urine samples of NB patients (n = 29).
RESULTS: 3MT and NMN showed an excellent diagnostic performance with very high specificity (100% and 95.8%, respectively) and sensitivity (88.2% and 80.4%). ROC curves were obtained (AUC of 0.93 and 0.91 for 3MT and NMN, respectively) and optimal cut-offs that could discriminate between controls and NB patients were defined. A positive correlation between NMN levels in urine and plasma (p = .0017) was found. DISCUSSION: The determination of plasma 3MT and NMN should be taken in consideration as a new diagnostic tool for NB. Validation in prospective clinical studies in comparison to urinary catecholamines and metanephrines is warranted.
Copyright © 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diagnosis; Liquid chromatography-tandem mass spectrometry; Neuroblastoma; Plasma free metanephrines

Mesh:

Substances:

Year:  2019        PMID: 30822416     DOI: 10.1016/j.clinbiochem.2019.02.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  5 in total

1.  An LC-MRM assay for the quantification of metanephrines from dried blood spots for the diagnosis of pheochromocytomas and paragangliomas.

Authors:  Vincent R Richard; René P Zahedi; Shaun Eintracht; Christoph H Borchers
Journal:  Anal Chim Acta       Date:  2020-07-09       Impact factor: 6.558

2.  The noradrenergic profile of plasma metanephrine in neuroblastoma patients is reproduced in xenograft mice models and arise from PNMT downregulation.

Authors:  Karim Abid; Maja Beck Popovic; Katia Balmas Bourloud; Jacqueline Schoumans; Joana Grand-Guillaume; Eric Grouzmann; Annick Mühlethaler-Mottet
Journal:  Oncotarget       Date:  2021-01-05

3.  A high sensitivity LC-MS/MS method for measurement of 3-methoxytyramine in plasma and associations between 3-methoxytyramine, metanephrines, and dopamine.

Authors:  Laura Smy; Mark M Kushnir; Elizabeth L Frank
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2021-08-05

4.  Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma.

Authors:  Sebastiano Barco; Chiara Lavarello; Davide Cangelosi; Martina Morini; Alessandra Eva; Luca Oneto; Paolo Uva; Gino Tripodi; Alberto Garaventa; Massimo Conte; Andrea Petretto; Giuliana Cangemi
Journal:  Front Oncol       Date:  2022-06-10       Impact factor: 5.738

Review 5.  Biochemical Diagnosis of Catecholamine-Producing Tumors of Childhood: Neuroblastoma, Pheochromocytoma and Paraganglioma.

Authors:  Graeme Eisenhofer; Mirko Peitzsch; Nicole Bechmann; Angela Huebner
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-26       Impact factor: 6.055

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.